基本信息
浏览量:154
职业迁徙
个人简介
Dr. Junxuan "Johnny" Lu's research interests and expertise include angiogenesis, apoptosis, autophagy, cell cycle regulation, senescence, prostate and mammary carcinogenesis models, androgen and estrogen receptor signaling; Proteomics-iTRAQ; transcriptomics; metabolomics; PK/PD; biomarkers; immunity and cancer; and clinical translation research.
The major areas of ongoing studies in the Lu lab include:
Herbal compounds as novel cancer chemopreventive and therapeutic agents. The Lu lab faculty and associates discovered pyranocoumarins from Korean angelica as a novel class of anti-androgens. They are studying Korean angelica extract and compounds for anti-cancer efficacy and mechanisms using xenograft and transgenic models. They are planning clinical trials in prostate cancer patients with oncologists and urologists at Penn State Cancer Institute.
Next-gen selenium compounds for cancer chemoprevention. The Lu lab has used cell culture models (cancer, vascular endothelial cells) to identify the lead Se compounds with cancer chemopreventive potential and their cellular and molecular mechanisms. They assess in vivo efficacy in animal models including xenografts, transgenic and conditional knockout mice models. The Lu lab collaborates with chemist colleagues in the department to study novel selenium hybrid drugs.
Precision therapy of cancer. The Lu lab has contributed to the findings that hexokinase 2 (HK2) plays a crucial role in subsets of aggressive prostate cancer and the proof of principle that co-targeting HK2-mediated Warburg effect with 2-deoxyglucose and its ULK1-mediated anti-apoptotic autophagy with chloroquine remarkably regresses these cancers in mouse models. The lab is collaborating with oncologists to repurpose these drugs to cancer patients.
The major areas of ongoing studies in the Lu lab include:
Herbal compounds as novel cancer chemopreventive and therapeutic agents. The Lu lab faculty and associates discovered pyranocoumarins from Korean angelica as a novel class of anti-androgens. They are studying Korean angelica extract and compounds for anti-cancer efficacy and mechanisms using xenograft and transgenic models. They are planning clinical trials in prostate cancer patients with oncologists and urologists at Penn State Cancer Institute.
Next-gen selenium compounds for cancer chemoprevention. The Lu lab has used cell culture models (cancer, vascular endothelial cells) to identify the lead Se compounds with cancer chemopreventive potential and their cellular and molecular mechanisms. They assess in vivo efficacy in animal models including xenografts, transgenic and conditional knockout mice models. The Lu lab collaborates with chemist colleagues in the department to study novel selenium hybrid drugs.
Precision therapy of cancer. The Lu lab has contributed to the findings that hexokinase 2 (HK2) plays a crucial role in subsets of aggressive prostate cancer and the proof of principle that co-targeting HK2-mediated Warburg effect with 2-deoxyglucose and its ULK1-mediated anti-apoptotic autophagy with chloroquine remarkably regresses these cancers in mouse models. The lab is collaborating with oncologists to repurpose these drugs to cancer patients.
研究兴趣
论文共 225 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
PHARMACOLOGY RESEARCH & PERSPECTIVESno. 1 (2024): e1173-e1173
Cheng Jiang,Hyo-Jeong Lee, Guang-xun Li,Junming Guo, Barbara Malewicz, Yan Zhao,Eun-Ok Lee,Hyo-Jung Lee, Jae-Ho Lee, Min-Seok Kim,Sung-Hoon Kim,Junxuan Lu
crossref(2023)
crossref(2023)
crossref(2023)
crossref(2023)
Jae-Ho Lee,Sun Choi,Yoonji Lee,Hyo-Jeong Lee,Kwan-Hyun Kim,Kyoo-Seok Ahn, Hyunsoo Bae,Hyo-Jung Lee,Eun-Ok Lee, Kwang-Seok Ahn,Shi Yong Ryu,Junxuan Lü,
crossref(2023)
crossref(2023)
JOURNAL OF CLINICAL ONCOLOGYno. 6_suppl (2023): TPS404-TPS404
引用0浏览0引用
0
0
Jae-Ho Lee,Sun Choi,Yoonji Lee,Hyo-Jeong Lee,Kwan-Hyun Kim,Kyoo-Seok Ahn, Hyunsoo Bae,Hyo-Jung Lee,Eun-Ok Lee,Kwang-Seok Ahn,Shi Yong Ryu,Junxuan Lü,
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn